HSANZ Posters presented at the HSANZ/ANZSBT/ASTH Annual Scientific Meeting held in Hobart, Tasmania, Australia, 15-18 October 2006 P62 Relationship between JAK2 V617F mutation status and Mpl protein expression in myeloproliferative disease

Results Control subjects with a normal haematological profiles were all JAK2 V617F negative and expressed a variable amount of platelet Mpl protein (mean 80%±17, n=20). Patients with a myeloproliferative disease were variably positive for the mutation with JAK2 V617F detected in 73% of PV and 63% of ET patients. In these myeloproliferative patients, Mpl was reduced compared to the control group (PV 46%±34, p<0.01 and ET 38%±30, p<0.01), and within each diagnostic classification the JAK2 V617F positive cohort had reduced Mpl expression compared to the patients with JAK2 V617F negative myeloproliferative disease (JAK2 V617F positive PV 35%±28, n=20 compared to JAK2 V617F negative PV 86%±18, n=6 and JAK2 V617F positive ET 31%±21, n=21 compared to JAK2 V617F negative ET 50%±39, n=12).